Hygienicum, our site in Graz, has tested the Austrian national team for Covid-19 during games or training sessions in the south of Austria in the course of the Covid pandemic in recent months. As a thank you for their efforts, the Hygienicum team received a club pennant with the signatures of the athletes of the Austrian national team. Hygienicum now made this club pennant available for auction by the Lions Club in Graz.

Process contaminants such as 3-MCPD and 2-MCPD can be formed during the production and processing of food, e.g. (high-fat) bakery products, baby food and edible fats and oils made from natural ingredients. As of 01.01.2021, new maximum levels will apply to the sum of 3-MCPD and 3-MCPD fatty acid esters and glycidyl fatty acid esters in certain foods.

Have you ever heard of Superfoods? Do you know Superfoods? Are your products perhaps Superfoods? Superfoods, such as nuts and dried fruits, are very popular among consumers, especially now in the Christmas season. Do you already know how to ensure the safety and quality of your superfoods?

Alternaria toxins are mycotoxins that can occur in food. More than 70 different Alternaria toxins have been identified so far. The best-known Alternaria toxins are alternariol (AOH), alternariol monomethyl ether (AME), altertoxins (ALT), tentoxin (TEN) and tenuazonic acid (TeA). The GBA Group has detected Alternaria toxins in samples of peppers, cereals, tomatoes, strawberries and potatoes.

Several hazardous characteristics (carcinogenic, teratogenic, fetotoxic, cytotoxic) have been identified in laboratory studies. An exposure assessment by the European Food Safety Authority (EFSA) has found that AOH, AME and TeA exceed the toxicologically relevant limit in food.

Dr. Andreas Nechansky has taken over the role of Managing Director of ABF Pharmaceutical Services (Member of GBAGroup). Dr. Nechansky has proven his management skills as Site Manager of ABF since 2019, and brings over 20 years’ experience in the field of Pharmaceutical Development and biologics characterization.

As VP of Research and Analytical Development of JHL Biotech (Taiwan), he became an expert in biosimilar development spanning pre-clinical work to Phase III readiness, including overseeing and directing bioanalytical and immunogenicity operations. As co-founder and COO of Vela Laboratories, he was responsible for Business Development and GMP-certified analytical operations services.